Sawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the First Half Year Ending September 2023 and Fiscal Year Ending March 31, 2024
May 11, 2023 at 02:00 am EDT
Share
Sawai Group Holdings Co., Ltd. provided consolidated earnings guidance for the first half year ending September 2023 and fiscal year ending March 31, 2024. For the first half year, the company expects sales of JPY 105,700 million, operating profit of JPY 7,000 million, profit attributable to owners of parent of JPY 5,100 million and basic earnings per share of JPY 116.46.
For the full year, the company expects sales of JPY 217,200 million, operating profit of JPY 15,100 million, profit attributable to owners of parent of JPY 11,300 million and basic earnings per share of JPY 258.04.
Sawai Group Holdings Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of medical and over-the-counter drugs. The Company operates in two segments. The Japan segment is engaged in medical and healthcare-related businesses such as manufacture and sale of pharmaceuticals and medical devices, as well as various related businesses. The America segment is engaged in the sale of manufactured pharmaceutical products to wholesale stores in America. The company is also engaged in the research and development of pharmaceutical products.
Sawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the First Half Year Ending September 2023 and Fiscal Year Ending March 31, 2024